Revenio: Not a one-trick pony
Revenio is known as the global beacon of tonometers but these days the company is a noteworthy challenger in more extensive ophthalmic health technology. Imaging tools (previous CenterVue) play an increasing role in future growth and HOME products, as well as software business offer longer term growth promises. Business is growing very profitably, the market has sound growth drivers, and the products have strong competitive advantages. In addition, the company has an excellent track record of its ability to create value with investments in product development, structural reorganization, and new long-term growth templates
Login required
This content is only available for logged in users
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures08.06.2021
2020 | 21e | 22e | |
---|---|---|---|
Revenue | 61.1 | 79.3 | 102.5 |
growth-% | 23.41 % | 29.94 % | 29.21 % |
EBIT (adj.) | 19.2 | 27.2 | 37.1 |
EBIT-% (adj.) | 31.44 % | 34.34 % | 36.19 % |
EPS (adj.) | 0.58 | 0.82 | 1.10 |
Dividend | 0.32 | 0.40 | 0.55 |
Dividend % | 0.64 % | 1.41 % | 1.93 % |
P/E (adj.) | 86.56 | 34.53 | 25.93 |
EV/EBITDA | 61.53 | 26.72 | 19.03 |